SCHEMBL3222464

SCHEMBL3222464

Cc1ccc(Cl)c(Cl)c1.O=S(=O)(Cl)Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALKBH3 Q96Q83 1/20 0.49
MAPT P10636 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
PTGES2 Q9H7Z7 2/20 0.40
AHR P35869 1/20 0.40
TP53 P04637 1/20 0.40
HTR2A P28223 1/20 0.39
SLC6A4 P31645 1/20 0.39
KCNH2 Q12809 1/20 0.39
CDK1 P06493 1/20 0.39
CCNB1 P14635 1/20 0.39
CCNA2 P20248 1/20 0.39
CDK2 P24941 1/20 0.39
CDK7 P50613 1/20 0.39
CCNH P51946 1/20 0.39
CCNA1 P78396 1/20 0.39
RAPGEF4 Q8WZA2 1/20 0.38
ALDH1A1 P00352 4/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL156450 0.87
SCHEMBL29352576 0.87
Hydrochloric Acid SCHEMBL27964236 0.85 AHR (0.48) ALKBH3MAPTMEN1KMT2AAHR
Fluoride SCHEMBL7597154 0.85 AHR (0.48) ALKBH3MAPTMEN1KMT2AAHR
Ammonia Solution, Strong SCHEMBL7443104 0.85 AHR (0.48) ALKBH3MAPTMEN1KMT2AAHR
SCHEMBL4429440 0.84 CYP3A4 (0.46) MEN1KMT2ARAPGEF4ALDH1A1LMNA
SCHEMBL16346525 0.79 ALKBH3 (0.43) ALKBH3MAPTMEN1KMT2APTGES2
SCHEMBL1200665 0.77 TRPV4 (0.53) MEN1KMT2APTGES2ALDH1A1LMNA
SCHEMBL29907222 0.77 TRPV4 (0.53) MEN1KMT2APTGES2ALDH1A1LMNA
SCHEMBL1501254 0.77 KMT2A (0.42) ALKBH3MEN1KMT2APTGES2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103958475-B Heteroaryl hydroxamic acid derivatives and their use in the treatment, alleviation or prevention of viral diseases F. HOFFMANN-LA ROCHE AG (CH) 2015-11-25 CN disclosed
CN-103958475-A Heteroaryl hydroxamic acid derivatives and their use in the treatment, alleviation or prevention of viral diseases HOFFMANN LA ROCHE 2014-07-30 CN disclosed
US-20100029648-A1 11-Beta HSD1 Inhibitors XIANG JASON SHAOYUN 2010-02-04 US disclosed
US-7632838-B2 11-beta HSD1 inhibitors WYETH (US) 2009-12-15 US disclosed
US-7582771-B2 Process for the synthesis of cPLA2 inhibitors WYETH (US) 2009-09-01 US disclosed
EP-1981848-A2 11-BETA HSD1 INHIBITORS Wyeth (US) 2008-10-22 EP disclosed
US-20070219198-A1 11-Beta HSD 1 inhibitors WYETH (US) 2007-09-20 US disclosed
WO-2007092435-A2 11-BETA HSD1 INHIBITORS WYETH (US) 2007-08-16 WO disclosed
US-20050049296-A1 Process for the synthesis of cPLA2 inhibitors WYETH (US) 2005-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029648-A1 11-Beta HSD1 Inhibitors HSD11B1, HSD3B1, HSD11B2 ALKBH3 765/4885MAPT 3352/4885MEN1 1354/4885
US-20050049296-A1 Process for the synthesis of cPLA2 inhibitors PLA2G12A, ACOX3, CPA2 ALKBH3 1309/4885MAPT 4856/4885MEN1 3465/4885
US-20070219198-A1 11-Beta HSD 1 inhibitors HSD11B1, HSD11B2, HSD3B1 ALKBH3 814/4885MAPT 3097/4885MEN1 1687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.